Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric‐Bernstam, Herbert I. Hurwitz, Kanwal P. S. Raghav et al. · The Lancet Oncology · 2019
Cited by 574 works. doi:10.1016/s1470-2045(18)30904-5
Authors
- Funda Meric‐Bernstam
- Herbert I. Hurwitz
- Kanwal P. S. Raghav
- Robert R. McWilliams
- Marwan Fakih
- Ari M. Vanderwalde
- Charles Swanton
- Razelle Kurzrock
- Howard A. Burris
- Christopher J. Sweeney
- Ron Bose
- David Robert Spigel
- Mary Stanley Beattie
- Steven D. Blotner
- Alyssa Stone
- Katja Schulze
- Vaikunth Cuchelkar
- John Daniel Hainsworth
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
- A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives